Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

Jianlin Xu, Haitang Yang, Bo Jin, Yuqing Lou, Yanwei Zhang, Xueyan Zhang, Hua Zhong, Huiming Wang, Dan Wu & Baohui Han

*Scientific Reports* 6:36371; doi: 10.1038/srep36371; published online 04 November 2016; updated 01 December 2016

In this Article, Haitang Yang is incorrectly listed as being affiliated with the 'Department of Pathology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 230032, China'. The correct affiliation is listed below:

Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 230032, China.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016